[1]吕益忠,陈亚梅.宫颈腺癌及其血管内介入治疗[J].介入放射学杂志,2008,(10):750.
　LüYizhong,CHEN Yamei.Intravascular interventional therapy for uterine cervical adenocarcinoma[J].journal interventional radiology,2008,(10):750.

点击复制

宫颈腺癌及其血管内介入治疗()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［１］Chao A，Wang TH，Lee YS，et al．Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression［J］．Int J Cancer，２００６，１１９：９１－９８．
［２］Wong YH，Sahota DS，Cheung TH．et al．Expression pattern associated with radiotherapy sensitivity in cervical cancer［J］．Cancer，２００６，３：１８９－１９５．
［３］Fregnani JH，Latorre MR，Novik PR，et al．Assessment of pelvic lymph node micrometastatic disease in stages IB and IIA of carcinoma of the uterine cervix［J］．Int J Gynecol Cancer，２００６，１６：１１８８－１１９４．
［４］Baalbergen A，Ewing－Graham PC，Hop WC ，et al．Prognosticfa－ctors in adenocarcinoma of the uterine cervix［J］．Gynecol Oncol，２００４，９２：２６２－２６７．
［５］Noriyuki M，Sumi T，Zhi X，et al．Vascular endothelial growth factor，matrix metalloproteinases，and cyclooxygenase－２influence prognosis of uterine cervical cancer in young women［J］．Int J Oncol，２００７，３１：５３１－５３６．
［６］Lona M，Tomicic I，Dotlic S，et al．Denocarcinoma of uterine cervix－prognostic significance of clinicopathologic parameters［J］．Croat Med J，２００５，４６：３９７－４０３．
［７］Chargui R，Damak T，Khornsi B，et al．prognostic factors and clinicopathologic characteristics of invasive adencarcinoma of the uterine cervix［J］．Am J Obstet．Gynecol，２００６，１９４：４３－４８．
［８］Nagai N，Hirata E，Kusuda T，et al．Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvantchemotherapy with docetaxel and cisplatin：a case report［J］．Int J Gynecol Cancer，２００５，１５：１１８７－１１９０．
［９］程晓东，谢幸，吕卫国，等．局部晚期宫颈癌新辅助化疗临床应用的进展［J］．中华医学杂志，２００５，８５：２１５４－２１５６．
［１０］Leung TW，Xue WC，Cheung AN，et al．Proliferation to ap optosis ratio as a prognostic marker in adenocarcinoma of uterine cervix［J］．Gynecol Oncol，２００４，９２：８６６－８７２．
［１１］Rguel LO，Ramirez J，Perez H，et al．Matrix metallo pro－teinases－２，－３，and－９secreted H by explants of benign and malignant lesions of the uterine cervix［J］．Int J Gynecol Cancer，２００４，１４：３３３－３４０．
［１２］Tsui S，Inoe H，Yasuda K，et al．Reduced expression of PTEN protein and it s prognostic implications in invasive ductal carcinoma of the breast［J］．Oncology，２００５，６８：３３８２－３４０４．
［１３］Yoshida H，Sumi T，Hyun Y，et al．Expression of survivin and matrix metallo proteinases in adenocarcinoma and squamous cell carcinoma of the uterinecervix［J］．Oncol Rep，２００３，１０：４５－４９．
［１４］Recoules－Arche A，Rouzier R，Rey A，et al．Does adenocarci－noma of uterine cervix have a worse prognosis than squamous carcinoma ？［J］Gynecol Obstet Fertil，２００４，３２：１１６－１２１．
［１５］Kang S，Kim M，Park IA，et al．Levation of cyclooxygenase－２is related to lymph node metastasis in adenocarcinoma of uterine cervix［J］．Cancer Lett，２００６，２３７：３０５－３１１．
［１６］Kurooka M，Nuovo GJ ，Caligiuri MA，et al．Cellular localiza－tionand function of Fas ligand（CD９５L）in tumors［J］．Cancer Res，２００２，６２：１２６１－１２６５
［１７］Wei LH，Kuo ML ，Chen CA，et al．Interleukin－６in cervical－cancer：The relationship with VEGF［J］．Gynecol Oncol，２００１，８２：４９－５６．
［１８］Strecker EP，Heber R，Boos I，et al．Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical orendometrial cancer using the peripheral imp lantable port system（PIPS）：a feasibility study［J］．Cardiovasc Intervent Radiol，２００３，２６：１１８－１２０．
［１９］Ikeda O，Mizukami N，Murata Y，et al．Randomized comp a－rison of intraarterial chemotherapy versus intraarterial chemothe－rapy and gelfoam embolizationfor treatment of advanced cervical carcinoma ［J］．Cardiovasc Intervent Radiol，２００５，２８：７３６－７４３．
［２０］Kobayashi K，Furukawa A，Takahashi M，et al．Neoadjuvant intra－arterial chemotherapy for locally advanced uterine cervical cancer：clinical efficacy and factors influencing response［J］．Cardiovasc Intervent Radiol，２００３，２６：２３４－２４１．
［２１］Yokoyama Y，Dhanabal M，Griffioen AW，et al．Synergybetween angiostatin and endostatin：inhibition of ovariancancer growth［J］．Cancer Res，２０００，６０：２１９０－２１９６．
［２２］Kim KS，Park YS．Antitumor effects of angiostatin K１２３and end－ostatin genes coadministered by the hydrodynam２ics２based transfection method［J］．Oncol Res，２００５，１５：３４３－３５０．
［２３］Downs LS，Jr Rogers LM，Yokoyama Y，et al．Thalidomid－eand angiostatin inhibit tumor growth in a murine xenograftmodel of human cervical cancer［J］．Gynecol Oncol，２００５，９８：２０３－２１０．
［２４］Chi SL，Pizzo SV．Angiostatin is directly cytotoxic totumor cells at low extracellular pH：a mechanism dependent on cell surface associated ATP synthase［J］．Cancer Res，２００６，６６：８７５－８８２．
［２５］Hamano Y．Physiological levels of tumstatin，a fragment of colla－gen IV alpha３chain，are generated by MMP２９proteolysis and suppress angiogenesis via alpha V beta３integrin［J］．Cancer Cell，２００３，３：５８９２－６０１１．
［２６］Maeshima Y，Lively JC．Tumstatin，an endothelial cell specific inhihitor of protein synthesis［J］．Science，２００２，２９５：１４０－１４３．